Cited by 152Multiple Myeloma Research and TreatmentsBone health and treatmentsLymphoma Diagnosis and Treatment

The DOI matches its Crossref record; 122 of the 123 references it cites were found in a registry or an index.

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management

Open access

Rajkumar, S. Vincent·2011·American Journal of Hematology

DOI 10.1002/ajh.21913

Open this paper in CoChat — free account Open PDF

Abstract

Disease overview: Multiple myeloma is malignant plasma‐cell disorder that accounts for ∼∼10% of all hematologic malignancies. Diagnosis: The diagnosis requires (1) 10% or more clonal plasma cells on bone marrow examination or a biopsy‐proven plasmacytoma plus (2) evidence of end‐organ damage felt to be related to the underlying plasma cell disorder. Risk stratification: Patients with 17p deletion, t(4;14), t(14;16), t(14;20), and karyotypic deletion 13 or hypodiploidy are considered to have high‐risk myeloma. All others are considered to have standard‐risk disease. Risk‐adapted therapy: Standard‐risk patients are treated with nonalkylator‐based therapy such as lenalidomide plus low‐dose dexamethasone (Rd) followed by autologous stem‐cell transplantation (ASCT). If patients are tolerating the induction regimen treatment well, an alternative strategy is to continue initial therapy after stem‐cell collection, reserving ASCT for first relapse. High‐risk patients are treated with a bortezomib‐based induction followed by ASCT and then bortezomib‐based maintenance. Patients not eligible for ASCT can be treated with Rd for standard risk disease or a bortezomib‐based regimen if high‐risk features are present. To reduce toxicity, when using bortezomib, the once‐weekly dose is preferred; similarly, when using dexamethasone, the low‐dose approach (40 mg once a week) is preferred, unless there is a need for rapid disease control. Management of refractory disease: Patients with indolent relapse can be treated first with lenalidomide, bortezomib, or alkylators plus low‐dose corticosteroids. Patients with more aggressive relapse often require therapy with a combination of multiple active agents. The most promising new agents in development are pomalidomide and carfilizomib. Am. J. Hematol. 86:57–65, 2011. © 2010 Wiley‐Liss, Inc.

Integrity signals

Registry

Crossref · 10.1002/ajh.21913

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Abdelkefi, A., Ladeb, S., Torjman, L., Othman, T. B., Lakhal, A., Romdhane, N. B., Omri, H. E., Elloumi, M., Bellâaj, H., Jeddi, R., et al. (2007) · Blood · doi:10.1182/blood-2007-07-101212 · Cited by 125
Retracted
Cancer Statistics, 2010
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citation
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citation
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
The International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,367
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Self-citation
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citation
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Self-citation
Multiple Myeloma
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,309
Self-citation
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citation
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Self-citation
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
Kyle, R. A., & Rajkumar, S. V. (2008) · Leukemia · doi:10.1038/leu.2008.291 · Cited by 1,122
Self-citation
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Self-citation
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
Owen, R. G., Treon, S. P., Al-Katib, A. M., Fonseca, R., Greipp, P. R., McMaster, M. L., Morra, E., Pangalis, G. A., Miguel, J. F. S., Branagan, A. R., et al. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50082 · Cited by 922
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Self-citation
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J. W., Shaughnessy, J. D., Gutierrez, N. C., Stewart, A. K., Morgan, G. J., Ness, B. V., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886
Multiple myeloma
Kyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 884
Self-citation
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Self-citation
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
Facon, T. T. F., Mary, J., Hulin, C., Benboubker, L., Attal, M., Pegourié, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 864
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A. P., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G. G., Miguel, J. F. S., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
Self-citation
POEMS syndrome: definitions and long-term outcome
Dispenzieri, A. A., Kyle, R. A., Lacy, M. Q., Rajkumar, S. V., Therneau, T. M., Larson, D. R., Greipp, P. R., Witzig, T. E., Basu, R., Suárez, G. A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2299 · Cited by 817
Self-citation
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815
Self-citation
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 802
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Demo, S. D., Kirk, C. J., Aujay, M. A., Buchholz, T. J., Dajee, M., Ho, M. N., Jiang, J., Laidig, G. J., Lewis, E. R., Parlati, F., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4086 · Cited by 695
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Attal, M., Harousseau, J., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub‐Agha, I., Bourhis, J.-H., Garderet, L., Pegourié, B., et al. (2006) · Blood · doi:10.1182/blood-2006-05-022962 · Cited by 663
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Self-citation
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hájek, R., Spencer, A. G., Miguel, J. F. S., Robak, T., Dmoszyńska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 644
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Self-citation
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P. J., Harrison, S. J., Smyth, M. J., & Prince, H. M. (2009) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 611
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569
Self-citation
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., Palva, I. P., Oivanen, T., Corrado, C., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 547
High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: Up-front or Rescue Treatment? Results of a Multicenter Sequential Randomized Clinical Trial
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
Harousseau, J., Attal, M., Avet‐Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T. T. F., Casassus, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.9158 · Cited by 540
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Richardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citation
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
Dimopoulos, M. A., Terpos, E., Comenzo, R. L., Tosi, P., Beksaç, M., Sezer, O., Siegel, D. S. D., Lokhorst, H. M., Kumar, S. K., Rajkumar, S. V., et al. (2009) · Leukemia · doi:10.1038/leu.2009.89 · Cited by 479
Self-citation
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials
Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., PALVA, I. P., Oivanen, T. M., Corrado, C., et al. (1998) · Journal of Clinical Oncology · Cited by 470
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial
Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458
Smoldering Multiple Myeloma
Kyle, R. A., & Greipp, P. R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006123022405 · Cited by 454
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
Mateos, M., Richardson, P. G. G., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M. H., Špıčka, I., Petrucci, M. T., Palumbo, A. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0638 · Cited by 431
Pathogenesis of myeloma bone disease
Roodman, G. D. (2009) · Leukemia · doi:10.1038/leu.2008.336 · Cited by 398
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
Jagannath, S., Durie, B. G. M., Wolf, J. L., Camacho, E. S., Irwin, D. H., Lutzky, J., McKinley, M., Gabayan, E., Mazumder, A., Schenkein, D. P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05540.x · Cited by 396
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
Dispenzieri, A. A., Katzmann, J. A., Kyle, R. A., Larson, D. R., Melton, L. J., Colby, C. L., Therneau, T. M., Clark, R. J., Kumar, S. K., Bradwell, A. R., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60482-5 · Cited by 394
Self-citation
Solitary plasmacytoma of bone and asymptomatic multiple myeloma
Dimopoulos, M. A., Moulopoulos, L. A., Maniatis, A. G., & Alexanian, R. (2000) · Blood · doi:10.1182/blood.v96.6.2037 · Cited by 393
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Hulin, C., Facon, T. T. F., Rodon, P., Pegourié, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 379
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
Reeder, C. B., Reece, D. E., Kukreti, V., Chen, C. L., Trudel, S., Hentz, J. G., Noble, B. N., Pirooz, N. A., Spong, J., Píza, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 378
Clinical Course of Patients With Relapsed Multiple Myeloma
Kumar, S. K., Therneau, T. M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Rajkumar, S. V., Fonseca, R., Witzig, T. E., Lust, J. A., Larson, D. R., et al. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.7.867 · Cited by 365
Self-citation
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A. P., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149427 · Cited by 357
Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma
Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404801 · Cited by 351
Self-citation
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
Rajkumar, S. V., Rosiñol, L., Hussein, M. A., Catalano, J. V., Wiktor-Jędrzejczak, W., Lucy, L. M., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1853 · Cited by 343
Self-citation
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Harousseau, J., Attal, M., Leleu, X. P., Troncy, J., Pegourié, B., Stoppa, A., Hulin, C., Benboubker, L., Fuzibet, J., Renaud, M., et al. (2006) · PubMed · Cited by 333
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3
Barlogie, B., Anaissie, E. J., van Rhee, F., Haessler, J., Hollmig, K. A., Pineda‐Roman, M., Cottler‐Fox, M., Mohiuddin, A., Alsayed, Y. M., Tricot, G. J. K., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06639.x · Cited by 330
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Remstein, E. D., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2003) · Blood · doi:10.1182/blood-2003-03-0801 · Cited by 325
Self-citation
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317
Self-citation
POEMS syndrome
Dispenzieri, A. A. (2007) · Blood Reviews · doi:10.1016/j.blre.2007.07.004 · Cited by 315
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
Wijermans, P., Schaafsma, M. R., Termorshuizen, F., Ammerlaan, R., Wittebol, S. H., Sinnige, H. A. M., Zweegman, S., Kooy, M. V. M., van der Griend, R., Lokhorst, H. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1610 · Cited by 259
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
Waage, A., Gimsing, P., Fayers, P., Abildgaard, N., Ahlberg, L., Björkstrand, B., Carlson, K., Dahl, I., Forsberg, K., Gulbrandsen, N., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237974 · Cited by 242
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens
Kumar, S. K., Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., Lentzsch, S., Munshi, N. C., Niesvizky, R., et al. (2009) · Blood · doi:10.1182/blood-2009-04-205013 · Cited by 240
Self-citation
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
Giralt, S., Stadtmauer, E. A., Harousseau, J., Palumbo, A. P., Bensinger, W., Comenzo, R. L., Kumar, S. K., Munshi, N. C., Dispenzieri, A. A., Kyle, R. A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.127 · Cited by 237
Self-citation
Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis
Landgren, O., & Weiss, B. M. (2009) · Leukemia · doi:10.1038/leu.2009.134 · Cited by 231
Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement
Dispenzieri, A. A., Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Kyle, R. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Russell, S. J., Hayman, S. R., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.3.323 · Cited by 222
Self-citation
SOLITARY PLASMACYTOMA OF BONE AND EXTRAMEDULLARY PLASMACYTOMA
Dimopoulos, M. A., Kiamouris, C., & Moulopoulos, L. A. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70124-6 · Cited by 218
Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays
Katzmann, J. A., Dispenzieri, A. A., Kyle, R. A., Snyder, M. R., Plevak, M. F., Larson, D. R., Abraham, R. S., Lust, J. A., Melton, L. J., & Rajkumar, S. V. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.12.1575 · Cited by 215
Self-citation
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kyle, R. A. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.10.1371 · Cited by 211
Self-citation
Incidence of multiple myeloma in Olmsted County, Minnesota
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., & Melton, L. J. (2004) · Cancer · doi:10.1002/cncr.20652 · Cited by 201
Self-citation
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)
Zonder, J. A., Crowley, J. J., Hussein, M. A., Bolejack, V., Moore, D. F., Whittenberger, B. F., Abidi, M. H., Durie, B. G. M., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2010-08-303487 · Cited by 196
Monoclonal Gammopathy of Undetermined Significance, Waldenström Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment
Rajkumar, S. V., Dispenzieri, A. A., & Kyle, R. A. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.5.693 · Cited by 192
Self-citation
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
Kastritis, E., Zervas, K., Symeonidis, A. S., Terpos, E., Delimbassi, S., Anagnostopoulos, N. I., Michali, E., Zomas, A., Katodritou, E., Gika, D., et al. (2009) · Leukemia · doi:10.1038/leu.2008.402 · Cited by 186
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
Palumbo, A. P., Sezer, O., Kyle, R. A., Miguel, J. F. S., Orlowski, R. Z., Moreau, P., Niesvizky, R., Morgan, G. J., Comenzo, R. L., Sonneveld, P., et al. (2009) · Leukemia · doi:10.1038/leu.2009.122 · Cited by 148
Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma
Lacy, M. Q., Gertz, M. A., Dispenzieri, A. A., Hayman, S. R., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S. K., Greipp, P. R., Fonseca, R., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1179 · Cited by 147
Self-citation
VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma
Pineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J., et al. (2008) · Leukemia · doi:10.1038/leu.2008.99 · Cited by 139
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients
Mazumder, A., Kaufman, J., Niesvizky, R., Lonial, S., Vesole, D., & Jagannath, S. (2008) · Leukemia · doi:10.1038/sj.leu.2405035 · Cited by 126
Management of multiple myeloma: a systematic review and critical appraisal of published studies
Kumar, A., Loughran, T., Alsina, M., Durie, B. G., & Djulbegovic, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01077-5 · Cited by 113
Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
van Rhee, F., Szymonifka, J. D., Anaissie, E. J., Nair, B. P., Waheed, S., Alsayed, Y. M., Petty, N. M., Shaughnessy, J. D., Hoering, A., Crowley, J. J., et al. (2010) · Blood · doi:10.1182/blood-2010-01-264333 · Cited by 107
The molecular characterization and clinical management of multiple myeloma in the post-genome era
Zhou, Y., Barlogie, B., & Shaughnessy, J. D. (2009) · Leukemia · doi:10.1038/leu.2009.160 · Cited by 107
Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
Haessler, J., Shaughnessy, J. D., Zhan, F., Crowley, J. J., Epstein, J., van Rhee, F., Anaissie, E. J., Pineda‐Roman, M., Zangari, M., Hollmig, K. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0527 · Cited by 101
Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant
Hari, P. N., Zhang, M.-J., Roy, V, Pérez, W. S., Bashey, A., To, L. B., Elfenbein, G., Freytes, C. O., Gale, R. P., Gibson, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.61 · Cited by 100
Treatment of newly diagnosed myeloma
Palumbo, A., & Rajkumar, S. V. (2008) · Leukemia · doi:10.1038/leu.2008.325 · Cited by 95
Self-citation
Transplantation for multiple myeloma: who, when, how often?
(2003) · Blood · doi:10.1182/blood-2003-01-0073 · Cited by 88
Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenström's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System
Baldini, L., Goldaniga, M. C., Guffanti, A., Broglia, C. M., Cortelazzo, S., Rossi, A., Morra, E., Colombi, M., Callea, V., Pogliani, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.147 · Cited by 83
Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
McCarthy, P., Owzar, K., Anderson, K. C., Hofmeister, C. C., Hassoun, H., Hurd, D. D., Stadtmauer, E. A., Giralt, S., Hárs, V., Linker, C. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8017 · Cited by 82
Many facets of bortezomib resistance/susceptibility
Kumar, S. K., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2008-07-167767 · Cited by 81
Self-citation
Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).
Cavo, M., Patriarca, F. F., Tacchetti, P., Galli, M., Perrone, G., Petrucci, M. T., Brioli, A., Bringhen, S., Pantani, L., Tosi, P., et al. (2007) · Blood · doi:10.1182/blood.v110.11.73.73 · Cited by 77
Treatment of Myeloma: Cure vs Control
Rajkumar, S. V. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.10.1142 · Cited by 75
Self-citation
Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance?
Gobbi, P. G., Baldini, L., Broglia, C. M., Goldaniga, M. C., Comelli, M., Morel, P., Morra, E., Cortelazzo, S., Bettini, R., & Merlini, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1899 · Cited by 71
Role of autologous and allogeneic stem cell transplantation in myeloma
Bensinger, W. (2009) · Leukemia · doi:10.1038/leu.2008.396 · Cited by 60
Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy.
Wang, M. L., Delasalle, K. B., Giralt, S. A., & Alexanian, R. (2005) · Blood · doi:10.1182/blood.v106.11.784.784 · Cited by 59
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50062 · Cited by 58
Self-citation
Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).
Richardson, P. G. G., Chanan-Khan, A. A., Schlossman, R. L., Munshi, N. C., Wen, P. Y., Briemberg, H., Kuter, D. J., Oaklander, A.-L., Lonial, S., Hassoun, H., et al. (2004) · Blood · doi:10.1182/blood.v104.11.336.336 · Cited by 57
Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma
Gutman, D., Morales, A. A., & Boise, L. H. (2009) · Leukemia · doi:10.1038/leu.2009.123 · Cited by 53
Myeloma bone disease: Pathogenetic mechanisms and clinical assessment
Silvestris, F., Lombardi, L., Matteo, M. D., Bruno, A., & Dammacco, F. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.04.014 · Cited by 53
A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.
Palumbo, A. P., Dimopoulos, M. A., Delforge, M., Kropff, M. H., Foà, R., Yu, Z., Herbein, L., Mei, J. M., Jacques, C. J., & Catalano, J. V. (2009) · Blood · doi:10.1182/blood.v114.22.613.613 · Cited by 48
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD.
Cavo, M., Tacchetti, P., Patriarca, F. F., Petrucci, M. T., Pantani, L., Galli, M., Raimondo, F. D., Crippa, C., Bringhen, S., Offidani, M., et al. (2009) · Blood · doi:10.1182/blood.v114.22.351.351 · Cited by 48
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial
Dispenzieri, A. A., Jacobus, S. J., Vesole, D. H., Callandar, N., Fonseca, R., & Greipp, P. (2010) · Leukemia · doi:10.1038/leu.2010.129 · Cited by 48
A Prospective, Multicenter, Randomized, Trial of Bortezomib/Melphalan/Prednisone (VMP) Versus Bortezomib/Thalidomide/Prednisone (VTP) as Induction Therapy Followed by Maintenance Treatment with Bortezomib/Thalidomide (VT) Versus Bortezomib/Prednisone (VP) in Elderly Untreated Patients with Multiple Myeloma Older Than 65 Years.
Mateos, M., Oriol, A., Martínez‐López, J., Cibeira, M. T., Gutierrez, N. C., Terol, M. J., de Paz, R., García‐Laraña, J., Bengoechea, E., Martı́n, A., et al. (2009) · Blood · doi:10.1182/blood.v114.22.3.3 · Cited by 45
Comparable Survival in Newly Diagnosed Multiple Myeloma (MM) after VAD Induction with High Dose Therapy Using Melphalan 140mg/M2 + TBI 12 Gy (MEL+TBI) Versus Standard Therapy with VBMCP and No Benefit from Interferon (IFN) Maintenance: Final Clinical Results of Intergroup Trial S9321 in the Context of IFM 90 and MRC VII Trials.
Crowley, J. J., Fonseca, R., Greipp, P. R., McCoy, J., & Barlogie, B. (2004) · Blood · doi:10.1182/blood.v104.11.539.539 · Cited by 45
Lenalidomide maintenance after transplantation for myeloma.
Attal, M., Cristini, C., Marit, G., Caillot, D., Facon, T. T. F., Hulin, C., Moreau, P., Mathiot, C., Avet‐Loiseau, H., Harousseau, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8018 · Cited by 45
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.
Richardson, P. G. G., Jagannath, S., Jakubowiak, A. J., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Mazumder, A., Munshi, N. C., Vesole, D. H., et al. (2008) · Blood · doi:10.1182/blood.v112.11.1742.1742 · Cited by 42
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial
Moreau, P., Hulin, C., Marit, G., Caillot, D., Facon, T., Lenain, P., Berthou, C., Pégourié, B., Stoppa, A. M., Casassus, P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.82 · Cited by 39
Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma
Gertz, M. A., Lacy, M., Inwards, D., Chen, M., Pineda, A., Gastineau, D., Greipp, P., Lust, J., Tefferi, A., Witzig, T., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701559 · Cited by 38
Reduced-intensity allogeneic transplantation for myeloma: reality bites
Stewart, A. K. (2009) · Blood · doi:10.1182/blood-2008-12-173526 · Cited by 35
Novel Three– and Four–Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.
Kumar, S. K., Flinn, I. W., Hari, P., Callander, N. S., Noga, S. J., Stewart, A. K., Glass, J., Raje, N. S., Rifkin, R. M., Shi, H., et al. (2009) · Blood · doi:10.1182/blood.v114.22.127.127 · Cited by 34
Self-citation
Biochemical markers of bone turnover in diagnosis of myeloma bone disease
Dızdar, Ö., Barışta, İ., Kalyoncu, U., Karadağ, Ö., Hasçelik, G., Cila, A., Pinar, A., Celik, I., Kars, A., & Tekuzman, G. (2006) · American Journal of Hematology · doi:10.1002/ajh.20794 · Cited by 32
Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.
Moreau, P., Facon, T. T. F., Attal, M., Doyen, C., Hulin, C., Marit, G., Garderet, L., Tiab, M., Avet‐Loiseau, H., & Harousseau, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.8014 · Cited by 30
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.
Palumbo, A., Bringhen, S., Rossi, D., Ria, R., Offidani, M., Patriarca, F. F., Nozzoli, C., Levi, A., Guglielmelli, T., Benevolo, G., et al. (2009) · Blood · doi:10.1182/blood.v114.22.128.128 · Cited by 27
Superiority of Double over Single Autologous Stem Cell Transplantation as First-Line Therapy for Multiple Myeloma.
Cavo, M., Cellini, C., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Vivo, A. D., Perrone, G., Lemoli, R. M., Tura, S., et al. (2004) · Blood · doi:10.1182/blood.v104.11.536.536 · Cited by 27
Single Versus Tandem High Dose Therapy (HDT) Supported with Autologous Blood Stem Cell (ABSC) Transplantation Using Unselected or CD34-Enriched ABSC: Long-Term Results of a Two by Two Designed Randomized Trial in 225 Young Patients with Multiple Myeloma (MM). for the Group “Myelome-Autogreffe”, Caen, Creteil, Limoges, Paris, Strasbourg, France.
Fermand, J., Desseaux, K., & Marolleau, J. P. (2009) · Blood · doi:10.1182/blood.v114.22.2320.2320 · Cited by 26
A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.
Palumbo, A., Cavo, M., Bringhen, S., Cavalli, M. M., Patriarca, F. F., Rossi, D., Tacchetti, P., Pescosta, N., Crippa, C., Galli, M., et al. (2009) · Blood · doi:10.1182/blood.v114.22.492.492 · Cited by 21
Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.
Kapoor, P., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Dingli, D., Kyle, R. A., Gertz, M. A., Greipp, P. R., Kumar, S. K., & Mandrekar, S. J. (2009) · Blood · doi:10.1182/blood.v114.22.615.615 · Cited by 19
Self-citation
Optimising bortezomib in newly diagnosed multiple myeloma
Rajkumar, S. V. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70199-6 · Cited by 7
Self-citation
Evidence for Cytogenetic and Fluorescence in Situ Hybridization (FISH) Risk Stratification of Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.
Kapoor, P., Fonseca, R., Rajkumar, S. V., Sinha, S., Gertz, M. A., Stewart, A. K., Bergsagel, P. L., Lacy, M. Q., Dingli, D., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1802.1802 · Cited by 3
Self-citation
A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
Durie, B. G. M., & Salmon, S. E. (1975) · Cancer · doi:10.1002/1097-0142(197509)36:3

Research works printed but not linked: 10

10.4065/80.10.1371 · DOI
10.1016/S0025-6196(11)61029-X · DOI
Jacobus S, 2010, Outcome of elderly patients 70 years and older with newly diagnosed myeloma in the ECOG randomized trial of lenalidomide/high‐dose dexamethasone (RD) versus lenalidomide/low‐dose dexamethasone (Rd), Haematologica, 95, 149
Barlogie B, 2003, Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m2 + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: Results of intergroup Trial S9321, Blood, 102, 42a
Blade J, 2003, High‐dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from PETHEMA after a median follow‐up of 66 months, Blood, 102, 42a
Attal M, 2002, Double autologous transplantation improves survival of multiple myeloma patients: Final analysis of a Prospective Randomized Study of the “Intergroupe Francophone du Myelome” (IFM 94), Blood, 100, 5a
Fermand JP, 2003, Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34‐enriched ABSC: Results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM), Hematol J, 4, S59
Goldschmidt H, 2003, Single vs. tandem autolgous transplantation in multiple myeloma: The GMMG experience, Hematol J, 4, S61
Kumar S, 2010, Outcome of patients with myeloma relapsing after IMiD and bortezomib therapy: A multicenter study from the International Myeloma Foundation Working Group, Haematologica, 95
Berenson JR, 2003, Experience with long‐term therapy using the proteasome inhibitor, bortezomib, in advanced multiple myeloma (MM), Proc Am Soc Clin Oncol, 22, 581

Sorted by citations

Multiple myeloma
Röllig, C., Knop, S. T., & Bornhäuser, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60493-1 · Cited by 626
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma
Zavidij, O., Haradhvala, N. J., Mouhieddine, T. H., Sklavenitis-Pistofidis, R., Cai, S., Reidy, M., Rahmat, M., Flaifel, A., Ferland, B., Su, N. K., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0053-3 · Cited by 374
Epidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Campagnaro, E. L., Castillo, J. J., Chandler, J. C., Costello, C. L., Efebera, Y. A., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 283
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Mateos, M., Blacklock, H. A., Schjesvold, F. H., Oriol, A., Simpson, D., George, A., Goldschmidt, H., Larocca, A., Chanan-Khan, A. A., Sherbenou, D. W., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30110-3 · Cited by 259

See all 152

Authors: Rajkumar, S. V.
Affiliations: Mayo Clinic (US)
Corresponding author: Rajkumar, S. Vincent
ORCID: Rajkumar, S. Vincent
Venue: American Journal of Hematology
Publisher: Wiley
Published: 2010-12-22
Volume: 86
Issue: 1
Pages: 57-65
ISSN: 0361-8609 (ISSN-L)
1096-8652
DOI: 10.1002/ajh.21913
OpenAlex: W2121283512
Cited by: 152
References: 123
Citations by year: 2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 10 · 2018: 3 · 2017: 9 · 2016: 7 · 2015: 10 · 2014: 20 · 2013: 23 · 2012: 24
FWCI: 3.28
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: American Journal of Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords: multiple myeloma, diagnosis, risk stratification, high-risk myeloma, lenalidomide, bortezomib, autologous stem cell transplantation, maintenance therapy, relapsed multiple myeloma, low-dose dexamethasone, 17p deletion, plasmacytoma, pomalidomide
MeSH terms: Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma, Risk Factors, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks